AdipoGen Life Sciences

anti-TLR8 (human), mAb (ABM15F6)

CHF 390.00
In stock
AG-20T-0307-C100100 µgCHF 390.00
More Information
Product Details
Synonyms Toll-like Receptor 8; CD288
Product Type Monoclonal Antibody
Properties
Clone ABM15F6
Isotype Mouse IgG1κ
Immunogen/Antigen Recombinant human TLR8 protein (aa 750-900).
Application

Flow Cytometry: (0.5-2μg/106 cells)
Immunohistochemistry: (5μg/ml; paraffin sections)

Optimal conditions must be determined individually for each application.

Crossreactivity Human
Specificity

Recognizes human TLR8.

Purity Protein G purified.
Concentration 0.5mg/ml
Formulation Liquid. In PBS containing 0.05% BSA and 0.05% sodium azide.
Isotype Negative Control

Mouse IgG1 Isotype Control

Accession Number Q9NR97
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Stable for at least 6 months after receipt when stored at +4°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description

TLR8 (Toll-like Receptor 8) is a member of the TLR (Toll-like receptor) family that plays a fundamental role in pathogen recognition and activation of innate immunity. TLR8 is a nucleotide-sensing TLR. TLR8 and TLR7 recognize single-stranded RNA (ssRNA) sequences containing GU-rich or poly-U sequences as their natural ligands, and they are also activated by synthetic small-molecular-weight compounds of the imidazoquinoline family. Both TLR8 and TLR7 signal via MYD88 and TRAF6, leading to NF-κB and antiviral factor, such as IRF family activation, cytokine secretion and the inflammatory response. They are localized intracellularly to endosomal membranes and act as potent activators of innate immune responses upon viral infection. The TLR8 gene is predominantly expressed in lung and peripheral blood leukocytes and lies in close proximity to TLR7 on chromosome X. Genetic variants in TLR8 have been linked to susceptibility to pulmonary tuberculosis. Recently, small molecule TLR7/8 agonists have demonstrated potential as vaccine adjuvants, since they directly activate antigen-presenting cells (APCs) and can enhance both humoral and cellular immune responses, especially Th1 responses. This makes the TLR7/8 signaling pathways interesting therapeutic targets.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.